Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Colorectal Neoplasms 20Rectal Neoplasms 12Colonic Neoplasms 11Head and Neck Neoplasms 6Neoplasm Metastasis 5Carcinoma, Hepatocellular 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Neoplasms 3Keratosis, Actinic 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Skin Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Nasopharyngeal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Biliary Tract Neoplasms 2Adenocarcinoma Of Esophagus 2Tongue Neoplasms 1Recurrence 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Motor Activity 1Melanoma 1Malignant Tumor of Pancreas Metastatic to Liver 1Lymphoma, Non-Hodgkin 1

Interventions

Nivolumab 17Ipilimumab 14pembrolizumab 11Cyclophosphamide 8trametinib 7dabrafenib 6Interleukin-2 6aldesleukin 5Vemurafenib 5Radiotherapy 5sargramostim 4130-nm albumin-bound paclitaxel 4fludarabine 3encorafenib 3binimetinib 3Specimen Handling 3Radiosurgery 3Melphalan 3Granulocyte-Macrophage Colony-Stimulating Factor 3fludarabine phosphate 2Magnetic Resonance Spectroscopy 2Introns 2Infliximab 2Celecoxib 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 2Albumin-Bound Paclitaxel 2yeast-CEA vaccine 1vitespin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Melanoma × Fluorouracil × Clear all
NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡